At roughly that time the company said it had not yet had an RFI from the regulators. They at no time after that said they received an RFI or completed their response with one exception when a corporate officer was quoted as saying they were completing an RFI, but no specifics were provided.
NWBO's trial was extremely complicated, it required all four regulators agreeing to changes in the protocol and goals mid trial. Hopefully our submission will be much easier to handle, but I'm sure they'll be through as this is essentially a new class of Alzheimer's medication.
Market Data 
Markets 
